Skip to content

The impact of synthesis bio-Nano materials in acceleration blood clotting

Survey efficiency of association of synthesis bio-Nano materials and duration of use of sandbags on the severity of low back pain and vascular complications of angiography area in patients referred to Dr Heshmat teaching center in Rasht city 2016

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201610271083N8
Enrollment
105
Registered
2016-11-20
Start date
2016-11-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Control of bleeding in angiography area. Ischaemic heart diseases

Interventions

Intervention 1: In group A patients will be followed by routine methods. Intervention 2: In group B, after leaving sheet, initial homeostasis simultaneously with the pressure and the use of 5 g synthe
Treatment - Other
In group A patients will be followed by routine methods.
In group B, after leaving sheet, initial homeostasis simultaneously with the pressure and the use of 5 g synthesis bio-Nano materials in angiography area until coagulation and bleeding will stop.Aft
In group C, after leaving sheet, initial hemostasis simultaneously with the pressure and the use of 5 g synthesis bio-Nano materials in the agiography area until coagulation and bleeding will stop.

Sponsors

Deputy of research and technology, Guilan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Included criteria: age over 18 years old; angiography via the femoral artery; the artery puncture to meet only once; F6 and F7 to achieve arteries using sheets; lack of a thrombolytic therapy and bleeding disorders; lack of deep vein thrombosis before the procedure; lack of previous experience back pain. Excluded criteria: systolic blood pressure higher than 160 mm Hg and diastolic blood pressure higher than 100 mm Hg; complications such as hematoma and bleeding during procedures; cardiac arrhythmia and lack of consciousness during and after coronary angiography; a history of drug allergy; immune deficiency or the use of drugs that weaken the immune system; pregnant or lactating women.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Hemostasis time. Timepoint: After of exhaust of catheter angiography. Method of measurement: Stopwatch.;Amount of bleeding. Timepoint: Up to 2 hours, every 15 minutes and then every hour until tenth hour and finally at the morning after angiography. Method of measurement: Weighing gauze soaked with blood with Precision scales for 0001/0.;Size of hematoma. Timepoint: Up to 2 hours, every 15 minutes and then every hour until tenth hour and finally at the morning after angiography. Method of measurement: Using transparent ruler.;Intensity of pain. Timepoint: At entrance, between the second and third hours- By ten o'clock every hour, and then the day after angiography. Method of measurement: VAS.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMajid Pourshaikhian

Guilan University of Medical Sciences-Nursing and Midwifery School of Rasht

pourshaikhian_m@yahoo.comm_pourshaikhan@gums.ac.ir+98 13 3336 2889

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026